  {"id":45833,"date":"2021-04-27T11:00:58","date_gmt":"2021-04-27T02:00:58","guid":{"rendered":"http:\/\/www.veeva.com\/jp\/?p=45833"},"modified":"2021-04-27T10:53:16","modified_gmt":"2021-04-27T01:53:16","slug":"parexel-and-veeva-partner-to-accelerate-clinical-trials","status":"publish","type":"post","link":"https:\/\/www.veeva.com\/jp\/news\/parexel-and-veeva-partner-to-accelerate-clinical-trials\/","title":{"rendered":"Parexel\u793e\u3068³Ô¹Ï±¬ÁÏ\u304c\u63d0\u643a\u3057\u3001\u81e8\u5e8a\u8a66\u9a13\u3092\u52a0\u901f"},"content":{"rendered":"<p style=\"text-align: center;\">\uff5e \u81e8\u5e8a\u8a66\u9a13\u306e\u30c6\u30af\u30ce\u30ed\u30b8\u30fc\u3068\u30d7\u30ed\u30bb\u30b9\u3092\u9032\u5316\u3055\u305b\u308b\u305f\u3081\u306e\u6226\u7565\u7684\u30b3\u30e9\u30dc\u30ec\u30fc\u30b7\u30e7\u30f3 \uff5e<\/p>\n<p>&nbsp;<\/p>\n<p style=\"text-align: right;\">2021\u5e744\u670827\u65e5<\/p>\n<p style=\"text-align: right;\">³Ô¹Ï±¬ÁÏ Japan\u682a\u5f0f\u4f1a\u793e<\/p>\n<p><strong><a href=\"https:\/\/www.parexel.com\/\">Parexel<\/a><\/strong>\u793e\u3068³Ô¹Ï±¬ÁÏ Systems\u3010NYSE:VEEV\u3011(\u672c\u793e : \u30ab\u30ea\u30d5\u30a9\u30eb\u30cb\u30a2\u5dde\u30d7\u30ec\u30b6\u30f3\u30c8\u30f3\u3001\u65e5\u672c\u6cd5\u4eba \u672c\u793e : \u6771\u4eac\u90fd\u6e0b\u8c37\u533a\u3001\u65e5\u672c\u6cd5\u4eba\u4ee3\u8868\u53d6\u7de0\u5f79 : \u5ca1\u6751 \u5d07\u3001\u4ee5\u4e0b ³Ô¹Ï±¬ÁÏ) \u306f\u3001\u30c6\u30af\u30ce\u30ed\u30b8\u30fc\u3068\u30d7\u30ed\u30bb\u30b9\u306e\u30a4\u30ce\u30d9\u30fc\u30b7\u30e7\u30f3\u3092\u901a\u3058\u3066\u81e8\u5e8a\u8a66\u9a13\u3092\u52a0\u901f\u3055\u305b\u308b\u6226\u7565\u7684\u30b3\u30e9\u30dc\u30ec\u30fc\u30b7\u30e7\u30f3\u3092\u767a\u8868\u3057\u307e\u3057\u305f\u3002\u4ed6\u306b\u4f8b\u306e\u306a\u3044\u63d0\u643a\u306b\u3088\u308a\u3001\u4e16\u754c\u3092\u30ea\u30fc\u30c9\u3059\u308b\u533b\u85ac\u54c1\u958b\u767a\u696d\u52d9\u53d7\u8a17\u6a5f\u95a2\uff08CRO\uff09\u3067\u3042\u308bParexel\u793e\u3068\u3001\u81e8\u5e8a\u8a66\u9a13\u3092\u5f37\u529b\u306b\u5f8c\u62bc\u3057\u3059\u308b\u30c6\u30af\u30ce\u30ed\u30b8\u30fc\u30a4\u30ce\u30d9\u30fc\u30bf\u30fc\u3067\u3042\u308b³Ô¹Ï±¬ÁÏ\u304c\u3001\u305d\u308c\u305e\u308c\u4e16\u754c\u4e2d\u306e\u6570\u5343\u4ef6\u306b\u308f\u305f\u308b\u8a66\u9a13\u3067\u57f9\u3063\u305f\u304d\u308f\u3081\u3066\u6709\u76ca\u306a\u7d4c\u9a13\u3092\u878d\u5408\u3055\u305b\u3001\u8a66\u9a13\u52b9\u7387\u3092\u5411\u4e0a\u3055\u305b\u308b\u3053\u3068\u306b\u3088\u308a\u3001\u60a3\u8005\u69d8\u3078\u65b0\u305f\u306a\u6cbb\u7642\u3092\u8fc5\u901f\u306b\u63d0\u4f9b\u3059\u308b\u3053\u3068\u304c\u3067\u304d\u308b\u3088\u3046\u306b\u306a\u308a\u307e\u3059\u3002 (\u672c\u30ea\u30ea\u30fc\u30b9\u306f\u3001³Ô¹Ï±¬ÁÏ\u7c73\u56fd\u672c\u793e\u304c\u767a\u8868\u3057\u305f\u5831\u9053\u8cc7\u6599\u306e\u6284\u8a33\u3067\u3059\u3002\u539f\u6587\u306f<strong><a href=\"https:\/\/www.veeva.com\/resources\/parexel-and-veeva-partner-to-accelerate-clinical-trials\/\">\u3053\u3061\u3089<\/a><\/strong>\u304b\u3089\u304a\u8aad\u307f\u3044\u305f\u3060\u3051\u307e\u3059\u3002)<\/p>\n<p>&nbsp;<\/p>\n<p>\u3053\u306e\u63d0\u643a\u306e\u4e00\u74b0\u3068\u3057\u3066\u3001Parexel\u793e\u306f<strong><a href=\"https:\/\/www.veeva.com\/jp\/products\/vault-etmf\/\">³Ô¹Ï±¬ÁÏ Vault eTMF<\/a><\/strong>\u3001<strong><a href=\"https:\/\/www.veeva.com\/jp\/products\/vault-ctms\/\">Vault CTMS<\/a><\/strong>\u3001<strong><a href=\"https:\/\/www.veeva.com\/jp\/products\/vault-study-startup\/\">Vault Study Startup<\/a><\/strong>\u306a\u3069\u306e\u696d\u52d9\u3092\u30b9\u30ea\u30e0\u5316\u3059\u308b³Ô¹Ï±¬ÁÏ\u306e\u30af\u30ea\u30cb\u30ab\u30eb\u30aa\u30da\u30ec\u30fc\u30b7\u30e7\u30f3\u5411\u3051\u30a2\u30d7\u30ea\u30b1\u30fc\u30b7\u30e7\u30f3\u30b9\u30a4\u30fc\u30c8\u3092\u6a19\u6e96\u63a1\u7528\u3057\u307e\u3059\u3002\u30af\u30ea\u30cb\u30ab\u30eb\u30c7\u30fc\u30bf\u30de\u30cd\u30b8\u30e1\u30f3\u30c8\u5411\u3051\u306e<strong><a href=\"https:\/\/www.veeva.com\/jp\/products\/clinical-data-management\/\">³Ô¹Ï±¬ÁÏ Vault CDMS<\/a><\/strong>\u3082\u3001Parexel\u793e\u306e\u6a19\u6e96\u88fd\u54c1\u3068\u3057\u3066\u9867\u5ba2\u306b\u63d0\u4f9b\u3055\u308c\u308b\u4e88\u5b9a\u3067\u3059\u3002<\/p>\n<p>\u4e21\u793e\u306f\u9023\u643a\u3057\u3066\u6cbb\u9a13\u4f9d\u983c\u8005\u3068\u8a66\u9a13\u5b9f\u65bd\u533b\u7642\u6a5f\u95a2\u3001\u60a3\u8005\u69d8\u304b\u3089\u306e\u77e5\u898b\u3092\u3082\u3068\u306b\u3001³Ô¹Ï±¬ÁÏ\u306e\u30af\u30e9\u30a6\u30c9\u30c6\u30af\u30ce\u30ed\u30b8\u30fc\u3068Parexel\u793e\u306e\u81e8\u5e8a\u8a66\u9a13\u63d0\u4f9b\u30d7\u30ed\u30bb\u30b9\u3092\u7d99\u7d9a\u7684\u306b\u5411\u4e0a\u3055\u305b\u3066\u3044\u304d\u307e\u3059\u3002Parexel\u793e\u306f³Ô¹Ï±¬ÁÏ\u306e\u30af\u30ea\u30cb\u30ab\u30eb\u30aa\u30da\u30ec\u30fc\u30b7\u30e7\u30f3\u95a2\u9023\u88fd\u54c1\u3092\u65e9\u671f\u306b\u5229\u7528\u3057\u3001\u30d5\u30a3\u30fc\u30c9\u30d0\u30c3\u30af\u3092\u63d0\u4f9b\u3057\u3066\u3044\u304d\u307e\u3059\u3002\u5bfe\u8c61\u3068\u306a\u308b\u306e\u306f\u305f\u3068\u3048\u3070\u3001\u5206\u6563\u578b\u81e8\u5e8a\u8a66\u9a13\uff08decentralized clinical trials-DCT\uff09\u3068\u30ea\u30b9\u30af\u306b\u57fa\u3065\u304f\u54c1\u8cea\u30de\u30cd\u30b8\u30e1\u30f3\u30c8\uff08risk-based quality management-RBQM\uff09\u304a\u3088\u3073\u30b3\u30df\u30e5\u30cb\u30c6\u30a3\u30d9\u30fc\u30b9\u306e\u8a66\u9a13\u5b9f\u65bd\u533b\u7642\u6a5f\u95a2\u306b\u304a\u3051\u308b\u3001\u533b\u7642\u6a5f\u95a2\u3068\u60a3\u8005\u69d8\u3092\u30b5\u30dd\u30fc\u30c8\u3059\u308b\u305f\u3081\u306e\u30a4\u30ce\u30d9\u30fc\u30b7\u30e7\u30f3\u3067\u3059\u3002<\/p>\n<p>Parexel\u793e\u306eCEO\u3067\u3042\u308bJamie Macdonald\u6c0f\u306f\u6b21\u306e\u3088\u3046\u306b\u30b3\u30e1\u30f3\u30c8\u3057\u3066\u3044\u307e\u3059\u3002\u300c³Ô¹Ï±¬ÁÏ\u306e\u30af\u30ea\u30cb\u30ab\u30eb\u30bd\u30ea\u30e5\u30fc\u30b7\u30e7\u30f3\u3092\u63a1\u7528\u3059\u308b\u3053\u3068\u3067\u3001\u81e8\u5e8a\u8a66\u9a13\u30d7\u30ed\u30bb\u30b9\u3092\u30b9\u30ea\u30e0\u5316\u3057\u3066\u52b9\u7387\u5316\u3067\u304d\u308b\u305f\u3081\u3001\u6cbb\u9a13\u4f9d\u983c\u8005\u3068\u8a66\u9a13\u5b9f\u65bd\u533b\u7642\u6a5f\u95a2\u3001\u60a3\u8005\u69d8\u305d\u308c\u305e\u308c\u306e\u8a66\u9a13\u5b9f\u65bd\u3068\u53c2\u52a0\u304c\u5bb9\u6613\u306b\u306a\u308a\u307e\u3059\u3002\u4eca\u56de\u306e³Ô¹Ï±¬ÁÏ\u3068\u306e\u696d\u52d9\u63d0\u643a\u306e\u62e1\u5927\u306b\u3088\u308a\u3001\u304a\u5ba2\u69d8\u306b\u9ad8\u3044\u4fa1\u5024\u3092\u63d0\u4f9b\u3057\u3001\u60a3\u8005\u69d8\u306e\u4eba\u751f\u306b\u3053\u308c\u307e\u3067\u4ee5\u4e0a\u306b\u597d\u5f71\u97ff\u3092\u3082\u305f\u3089\u305b\u308b\u3053\u3068\u3092\u671f\u5f85\u3057\u3066\u3044\u307e\u3059\u3002\u300d<\/p>\n<p>³Ô¹Ï±¬ÁÏ\u306e\u5275\u8a2d\u8005\u517cCEO\u3067\u3042\u308bPeter Gassner\u306f\u6b21\u306e\u3088\u3046\u306b\u30b3\u30e1\u30f3\u30c8\u3057\u3066\u3044\u307e\u3059\u3002\u300cParexel\u793e\u3068\u306e\u63d0\u643a\u3067\u3001\u81e8\u5e8a\u7814\u7a76\u5206\u91ce\u306b\u304a\u3044\u3066\u304a\u5ba2\u69d8\u306e\u6210\u529f\u3092\u4fc3\u9032\u3057\u3001\u30a4\u30ce\u30d9\u30fc\u30b7\u30e7\u30f3\u3092\u52a0\u901f\u3067\u304d\u308b\u3053\u3068\u3092\u3046\u308c\u3057\u304f\u601d\u3044\u307e\u3059\u3002\u4e21\u793e\u306e\u9023\u643a\u306b\u3088\u308a\u79c1\u305f\u3061\u306e\u304a\u5ba2\u69d8\u306f\u3001\u65b0\u305f\u306a\u30ef\u30af\u30c1\u30f3\u3084\u8a3a\u65ad\u65b9\u6cd5\u3001\u88c5\u7f6e\u3001\u6cbb\u7642\u6cd5\u306a\u3069\u3092\u5fc5\u8981\u3068\u3059\u308b\u60a3\u8005\u69d8\u306e\u3082\u3068\u306b\u3088\u308a\u65e9\u304f\u304a\u5c4a\u3051\u3067\u304d\u308b\u3088\u3046\u306b\u306a\u308b\u3067\u3057\u3087\u3046\u3002\u300d<\/p>\n<p>&nbsp;<\/p>\n<p><strong>\u3010Parexel<\/strong><strong>\u793e\u306b\u3064\u3044\u3066\u3011<\/strong><br \/>\n\u30d1\u30ec\u30af\u30bb\u30eb\u306f\u3001\u4e16\u754c\u4e2d\u306e\u30e9\u30a4\u30d5\u30b5\u30a4\u30a8\u30f3\u30b9\u4f01\u696d\u3084\u30d0\u30a4\u30aa\u533b\u85ac\u54c1\u4f01\u696d\u304c\u3001\u79d1\u5b66\u7684\u306a\u767a\u898b\u3092\u65b0\u3057\u3044\u6cbb\u7642\u6cd5\u3078\u3068\u5909\u63db\u3059\u308b\u624b\u52a9\u3051\u3068\u306a\u308b\u69d8\u3005\u306a\u30b5\u30fc\u30d3\u30b9\u3092\u63d0\u4f9b\u3057\u3001\u60a3\u8005\u3055\u3093\u304c\u3088\u308a\u5065\u5eb7\u306b\u306a\u308b\u305f\u3081\u306e\u9769\u65b0\u7684\u3067\u65b0\u3057\u3044\u6cbb\u7642\u6cd5\u306e\u958b\u767a\u3092\u30b5\u30dd\u30fc\u30c8\u3057\u3066\u3044\u307e\u3059\u3002\u30d1\u30ec\u30af\u30bb\u30eb\u306e\u81e8\u5e8a\u8a66\u9a13\u652f\u63f4\u3001\u85ac\u4e8b\u30b3\u30f3\u30b5\u30eb\u30c6\u30a3\u30f3\u30b0\u3001\u305d\u3057\u3066\u5e02\u8ca9\u5f8c\u3084\u30de\u30fc\u30b1\u30c3\u30c8\u30a2\u30af\u30bb\u30b9\u306b\u308f\u305f\u308b\u9ad8\u3044\u5c02\u9580\u6027\u3084\u9ad8\u5ea6\u306a\u30c6\u30af\u30ce\u30ed\u30b8\u30fc\u3001\u5e45\u5e83\u3044\u75be\u60a3\u9818\u57df\u306b\u304a\u3051\u308b\u80fd\u529b\u3068\u6a5f\u80fd\u6027\u306f\u3001\u30d1\u30ec\u30af\u30bb\u30eb\u306e\u5f37\u3044\u4fe1\u5ff5\u306b\u3088\u3063\u3066\u652f\u3048\u3089\u308c\u3066\u3044\u307e\u3059\u3002\u30d1\u30ec\u30af\u30bb\u30eb\u306f\u30012020\u5e7412\u6708\u306b\u30a4\u30f3\u30d5\u30a9\u30fc\u30de\u30fb\u30d5\u30a1\u30fc\u30de\u30fb\u30a4\u30f3\u30c6\u30ea\u30b8\u30a7\u30f3\u30b9\u306e\u72ec\u7acb\u30d1\u30cd\u30eb\u306b\u3088\u3063\u3066\u300c\u30d9\u30b9\u30c8CRO\u300d\u306b\u9078\u3070\u308c\u307e\u3057\u305f\u3002\u8a73\u7d30\u306b\u3064\u3044\u3066\u306f\u3001<a href=\"https:\/\/www.parexel.com\/\">website<\/a>\u3084<a href=\"https:\/\/www.linkedin.com\/company\/4451\">LinkedIn<\/a>\u3001<a href=\"https:\/\/twitter.com\/PAREXEL\">Twitter<\/a>\u3001<a href=\"https:\/\/www.instagram.com\/parexel_international\/\">Instagram<\/a>\u3092\u3054\u89a7\u304f\u3060\u3055\u3044\u3002<\/p>\n<p><strong>\u3010<\/strong><strong>³Ô¹Ï±¬ÁÏ Systems<\/strong><strong>\u793e\u306b\u3064\u3044\u3066\u3011<\/strong><br \/>\n³Ô¹Ï±¬ÁÏ Systems\u793e\u306f\u30b0\u30ed\u30fc\u30d0\u30eb\u306a\u30e9\u30a4\u30d5\u30b5\u30a4\u30a8\u30f3\u30b9\u4f01\u696d\u5411\u3051\u306b\u30af\u30e9\u30a6\u30c9\u30d9\u30fc\u30b9\u306e\u30bd\u30d5\u30c8\u30a6\u30a7\u30a2\u3092\u63d0\u4f9b\u3059\u308b\u30ea\u30fc\u30c7\u30a3\u30f3\u30b0\u30ab\u30f3\u30d1\u30cb\u30fc\u3067\u3059\u3002\u4e16\u754c\u6700\u5927\u898f\u6a21\u306e\u88fd\u85ac\u4f1a\u793e\u304b\u3089\u30d0\u30a4\u30aa\u30c6\u30af\u30ce\u30ed\u30b8\u30fc\u5206\u91ce\u306e\u65b0\u8208\u4f01\u696d\u307e\u3067\u3001975\u793e\u3092\u8d85\u3048\u308b\u9867\u5ba2\u306b\u6280\u8853\u9769\u65b0\u3078\u306e\u53d6\u308a\u7d44\u307f\u3084\u5353\u8d8a\u3057\u305f\u88fd\u54c1\u529b\u306b\u3088\u3063\u3066\u3001\u304a\u5ba2\u69d8\u306e\u6210\u529f\u306b\u30b3\u30df\u30c3\u30c8\u3059\u308b\u69d8\u3005\u306a\u30b5\u30fc\u30d3\u30b9\u3092\u63d0\u4f9b\u3057\u3066\u3044\u307e\u3059\u3002\u30d1\u30d6\u30ea\u30c3\u30af\u30fb\u30d9\u30cd\u30d5\u30a3\u30c3\u30c8\u30fb\u30b3\u30fc\u30dd\u30ec\u30fc\u30b7\u30e7\u30f3\u4f01\u696d\u3068\u3057\u3066³Ô¹Ï±¬ÁÏ\u306f\u3001\u9867\u5ba2\u3084\u5f93\u696d\u54e1\u3001\u63d0\u643a\u4f01\u696d\u3001\u682a\u4e3b\u3001\u30b5\u30fc\u30d3\u30b9\u63d0\u4f9b\u696d\u754c\u3092\u542b\u3080\u3059\u3079\u3066\u306e\u30b9\u30c6\u30fc\u30af\u30db\u30eb\u30c0\u30fc\u306e\u5229\u76ca\u30d0\u30e9\u30f3\u30b9\u3092\u4fdd\u3064\u3053\u3068\u306b\u30b3\u30df\u30c3\u30c8\u3057\u307e\u3059\u3002\u8a73\u3057\u304f\u306f\u3001<a href=\"https:\/\/veeva.com\/jp\/\">https:\/\/veeva.com\/jp\/<\/a>\u3092\u3054\u89a7\u304f\u3060\u3055\u3044\u3002<\/p>\n<p>&nbsp;<\/p>\n<p>\u3010Forward-looking Statements\u3011<\/p>\n<p>This release contains forward-looking statements, including the market demand for and acceptance of ³Ô¹Ï±¬ÁÏ\u2019s products and services, the results from use of ³Ô¹Ï±¬ÁÏ\u2019s products and services, and general business conditions (including the on-going impact of COVID-19), particularly within the life sciences industry. Any forward-looking statements contained in this press release are based upon ³Ô¹Ï±¬ÁÏ\u2019s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent ³Ô¹Ï±¬ÁÏ\u2019s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and ³Ô¹Ï±¬ÁÏ disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect ³Ô¹Ï±¬ÁÏ\u2019s financial results are included under the captions, \u201cRisk Factors\u201d and \u201cManagement\u2019s Discussion and Analysis of Financial Condition and Results of Operations,\u201d in the company\u2019s filing on Form 10-Q for the period ended October 31, 2020.This is available on the company\u2019s website at <a href=\"http:\/\/veeva.com\/\">veeva.com<\/a> under the Investors section and on the SEC\u2019s website at <a href=\"http:\/\/sec.gov\/\">sec.gov<\/a>. Further information on potential risks that could affect actual results will be included in other filings ³Ô¹Ï±¬ÁÏ makes with the SEC from time to time.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Parexel\u793e\u3068³Ô¹Ï±¬ÁÏ\u306f\u3001\u30c6\u30af\u30ce\u30ed\u30b8\u30fc\u3068\u30d7\u30ed\u30bb\u30b9\u306e\u30a4\u30ce\u30d9\u30fc\u30b7\u30e7\u30f3\u3092\u901a\u3058\u3066\u81e8\u5e8a\u8a66\u9a13\u3092\u52a0\u901f\u3055\u305b\u308b\u6226\u7565\u7684\u30b3\u30e9\u30dc\u30ec\u30fc\u30b7\u30e7\u30f3\u3092\u767a\u8868<\/p>\n","protected":false},"author":131,"featured_media":45836,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[322,341],"tags":[],"class_list":["post-45833","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-press-release","category-case-study"],"acf":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/www.veeva.com\/jp\/wp-json\/wp\/v2\/posts\/45833"}],"collection":[{"href":"https:\/\/www.veeva.com\/jp\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.veeva.com\/jp\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.veeva.com\/jp\/wp-json\/wp\/v2\/users\/131"}],"replies":[{"embeddable":true,"href":"https:\/\/www.veeva.com\/jp\/wp-json\/wp\/v2\/comments?post=45833"}],"version-history":[{"count":3,"href":"https:\/\/www.veeva.com\/jp\/wp-json\/wp\/v2\/posts\/45833\/revisions"}],"predecessor-version":[{"id":45840,"href":"https:\/\/www.veeva.com\/jp\/wp-json\/wp\/v2\/posts\/45833\/revisions\/45840"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.veeva.com\/jp\/wp-json\/wp\/v2\/media\/45836"}],"wp:attachment":[{"href":"https:\/\/www.veeva.com\/jp\/wp-json\/wp\/v2\/media?parent=45833"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.veeva.com\/jp\/wp-json\/wp\/v2\/categories?post=45833"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.veeva.com\/jp\/wp-json\/wp\/v2\/tags?post=45833"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}